25 related articles for article (PubMed ID: 17896941)
1. Binding Performance of Human Intravenous Immunoglobulin and 20(
Liu YC; Li YY; Yao XJ; Qi HL; Wei XX; Liu JN
Molecules; 2018 Sep; 23(9):. PubMed ID: 30231526
[TBL] [Abstract][Full Text] [Related]
2. Human serum albumin conjugates of 7-ethyl-10-hydroxycamptothecin (SN38) for cancer treatment.
Sepehri N; Rouhani H; Ghanbarpour AR; Gharghabi M; Tavassolian F; Amini M; Ostad SN; Ghahremani MH; Dinarvand R
Biomed Res Int; 2014; 2014():963507. PubMed ID: 24895635
[TBL] [Abstract][Full Text] [Related]
3. A Biophysical Insight of Camptothecin Biodistribution: Towards a Molecular Understanding of Its Pharmacokinetic Issues.
Almeida A; Fernandes E; Sarmento B; Lúcio M
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34204692
[TBL] [Abstract][Full Text] [Related]
4. Determination of hydroxycamptothecin affinities to albumin and membranes by steady-state fluorescence anisotropy measurements.
Ziomkowska B; Cyrankiewicz M; Kruszewski S
Comb Chem High Throughput Screen; 2007 Jul; 10(6):486-92. PubMed ID: 17896945
[TBL] [Abstract][Full Text] [Related]
5. The structural basis of camptothecin interactions with human serum albumin: impact on drug stability.
Burke TG; Mi Z
J Med Chem; 1994 Jan; 37(1):40-6. PubMed ID: 8289200
[TBL] [Abstract][Full Text] [Related]
6. The comparison of biophysical properties of DB-67 and its ester DB-67-4ABTFA determined by fluorescence spectroscopy methods.
Kruszewski S; Ziomkowska B; Cyrankiewicz M; Wybranowski T
Biosystems; 2008 Dec; 94(3):270-5. PubMed ID: 18718502
[TBL] [Abstract][Full Text] [Related]
7. Differential interactions of camptothecin lactone and carboxylate forms with human blood components.
Mi Z; Burke TG
Biochemistry; 1994 Aug; 33(34):10325-36. PubMed ID: 8068669
[TBL] [Abstract][Full Text] [Related]
8. Molecular dynamics simulations and experimental studies of binding and mobility of 7-tert-butyldimethylsilyl-10-hydroxycamptothecin and its 20(S)-4-aminobutyrate ester in DMPC membranes.
Xiang TX; Jiang ZQ; Song L; Anderson BD
Mol Pharm; 2006; 3(5):589-600. PubMed ID: 17009858
[TBL] [Abstract][Full Text] [Related]
9. Hydroxycamptothecin deactivation rates and binding to model membranes and HSA determined by fluorescence spectra analysis.
Ziomkowska B; Cyrankiewicz M; Kruszewski S
Comb Chem High Throughput Screen; 2007 Jul; 10(6):459-65. PubMed ID: 17896941
[TBL] [Abstract][Full Text] [Related]
10. Determination of camptothecin analogs in biological matrices by high-performance liquid chromatography.
Loos WJ; de Bruijn P; Verweij J; Sparreboom A
Anticancer Drugs; 2000 Jun; 11(5):315-24. PubMed ID: 10912947
[TBL] [Abstract][Full Text] [Related]
11. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
12. Clinical pharmacokinetics of irinotecan.
Chabot GG
Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
